Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KIF18A | Q8NI77 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647116 | 0.91 | SCN10A (0.46) | SCN10AMAPTMEN1KMT2APOLB | |
| SCHEMBL6646383 | 0.88 | SCN10A (0.47) | SCN10AMAPTMEN1KMT2APOLB | |
| SCHEMBL6645777 | 0.88 | SCN10A (0.43) | SCN10AMAPTMEN1KMT2APOLB | |
| SCHEMBL6644190 | 0.88 | OGA (0.52) | SCN10AMAPTMEN1KMT2APOLB | |
| SCHEMBL6646849 | 0.86 | SCN10A (0.41) | SCN10AMAPTMEN1KMT2APOLB | |
| SCHEMBL6649970 | 0.86 | ADRB2 (0.43) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL6647760 | 0.80 | SCN10A (0.45) | SCN10AMAPTMEN1KMT2APOLB | |
| SCHEMBL6648073 | 0.80 | SCN10A (0.43) | SCN10AMAPTMEN1KMT2APOLB | |
| SCHEMBL6645122 | 0.80 | OGA (0.59) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL6643435 | 0.80 | SCN10A (0.41) | SCN10AMAPTMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | SCN10A 1201/4885MAPT 4101/4885MEN1 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.